The purpose of this study was to provide periodic quality assurance (QA) methods for respiratory-gated proton beam with a range modulation wheel (RMW) and to clarify the characteristics and long-term stability of the respiratory-gated proton beam. A two-dimensional detector array and a solid water phantom were used to measure absolute dose, spread-out Bragg peak (SOBP) width and proton range for monthly QA. SOBP width and proton range were measured using an oblique incidence beam to the lateral side of a solid water phantom and compared between with and without a gating proton beam. To measure the delay time of beam-on/off for annual QA, we collected the beam-on/off signals and the dose monitor-detected pulse. We analyzed the results of monthly QA over a 15-month period and investigated the delay time by machine signal analysis. The dose deviations at proximal, SOBP center and distal points were −0.083 ± 0.25%, 0.026 ± 0.20%, and −0.083 ± 0.35%, respectively. The maximum dose deviation between with and without respiratory gating was −0.95% at the distal point and other deviations were within ±0.5%. Proximal and SOBP center doses showed the same trend over a 15-month period. Delay times of beam-on/off for 200 MeV/SOBP 16 cm were 140.5 ± 0.8 ms and 22.3 ± 13.0 ms, respectively. Delay times for 160 MeV/SOBP 10 cm were 167.5 ± 15.1 ms and 19.1 ± 9.8 ms. Our beam delivery system with the RMW showed sufficient stability for respiratory-gated proton therapy and the system did not show dependency on the energy and the respiratory wave form. The delay times of beam-on/off were within expectations. The proposed QA methods will be useful for managing the quality of respiratory-gated proton beams and other beam delivery systems.
| INTRODUCTION
In passive proton therapy systems, a range modulation wheel (RMW) is widely used to deliver a uniform depth dose to the target volume.
The RMW rotates and is gated with the proton beam output to provide a spread-out Bragg peak (SOBP). 1 Proton therapy for moving tumors has been investigated with passive or active scanning methods in many studies. [2] [3] [4] In general, the passive proton beam is more robust for moving tumors than active scanning methods. One technique to manage respiratory organ motion is to provide an extra margin in the treatment planning 5 and to use a respiratory gating system. 6, 7 To avoid dose uncertainties and limitations introduced by incomplete modulations, the passive proton therapy system with RMW features complete modulation cycles. 8 Quality assurance (QA) for respiratory gating therapy must include patient management and the respiratory gating system in tandem with the irradiation technology. The AAPM TG-76 report 9 indicates various configurations and techniques for respiratory gating and recommends that technology-specific QA should be employed. The AAPM TG-142 report 10 provides criteria and tolerances for respiratory-gated photon beams, and implementation of these tests has been reported. 11 These reports recommend that beam output and energy consistency be assured every month and year. In proton therapy, energy consistency is very important because the proton beam has a range that corresponds to its energy. Kase et al 12 reported a QA procedure for a proton therapy system including respiratory gating. However, they mentioned only output consistency with respiratory gating. A report on the proton machine QA procedures of the MD Anderson Cancer Center has also been published, 13 but did not mention respiratory gating.
Since the RMW proton beam is synchronized with beam output, it should be included in QA for the stabilities of beam output, SOBP width and beam range. Furthermore, complete modulation cycles must operate with respiratory gating, which can cause dose deviation or an irregular SOBP shape. In this study, we for the first time provide QA methods and clarify the characteristics and longterm stability of the respiratory-gated proton beam with RMW.
| MATERIALS AND METHODS

2.A | Beam delivery system
The accelerator at the Nagoya Proton Therapy Center (NPTC) is a synchrotron with a linac injector. The NPTC has both the passive scattering system and the spot scanning system. The synchrotron at the NPTC can produce 8 energies (from 100 to 250 MeV) for the passive method and 95 energies (from 71.6 to 221. 
2.C | Delay time measurements for the annual QA
As the annual QA, we observed three signals: the simulated respiratory wave signal, the respiratory gate-on/off signal, and the dose monitor pulse. The relationships of respiratory wave signal, gateon/off signal, beam-on/off signal, RMW modulation region, and dose monitor pulse are shown in Fig. 3 . The respiratory wave signal for the annual QA is simulated patient wave generated by the respiratory monitoring system (the first row of Fig. 3) . The 
2.D | Extra validation: the energy dependence and the effects of the realistic respiratory wave
As the extra validation, we measured the energy dependence to the dose distribution and the effects of the realistic respiratory wave to the dose distribution and delay times. Experimental materials and setup are the same as the monthly QA and the annual QA mentioned at Sections 2.B and 2.C. The energy dependence to the dose distribution was measured using the middle energy (160 MeV/SOBP 10 cm) and the low energy (120 MeV/SOBP 4 cm) proton beam. For the validation of the effects of the realistic respiratory wave, we used real recorded respiratory pattern from three patients that were treated using respiratory proton beam at the NPTC. Respiratory wave forms of these patients are shown in Fig. 4 . To measure the effects of the realistic respiratory wave, we used the reference condition (200 MeV/SOBP 10 cm). We measured the energy dependence and the effects of the realistic respiratory wave five times and summarized the average value and worst case.
3 | RESULTS −0.083 ± 0.25%, 0.026 ± 0.20%, and −0.083 ± 0.35%, respectively.
The maximum dose deviation between w/and w/o gating was −0.95% at distal and other deviations were within ±0.5%. 
| DISCUSSION
We reported periodic QA results of the respiratory gated proton beam and beam-on/off delay times when using RMW. In the TG-142 report, the tolerance of beam output constancy with the respiratory gating is recommended to be within 2%. 10 With regard to the QA of respiratory gating treatment, proton therapy systems are required to have the same accuracy. 12 From the results of this report, our system has sufficient stability. From the results of
Figs. 6, 7 and Table 1 , it is assumed that the dose deviation has no energy dependence and the effects of respiratory waves. As shown in Fig. 7 , the SOBP shapes between w/and w/o gating showed no remarkable change during a 15-month period, indicated
RMWs worked well regardless of respiratory gating. Beam energy constancy can be verified by the distal dose because 1-mm range error cause more than a 5% dose difference, so the range errors of our measurements were estimated to be less than 0. than 20 mm/s. From our results, the assumed maximum movement of object in our passively proton therapy system is 1.8 mm. Clinically, we have added extra 3 mm gating margin in the anterior direction to manage the impact of the beam-off delay time. Previous studies have also reported imaging time delays and energy dependences. 16, 17 Further investigation is required to determine the optimal extra gating margin for the respiratory-gated proton therapy using RMW.
In this study, we used an oblique incidence beam. An oblique incidence beam can detect the beam range and doses at multiple depths simultaneously with the same dose and the beam intensity of the clinical setting. Ideally, the multi-layer ionization chamber (MLIC)
is useful to detect the beam range and the SOBP width, however, the oblique incidence beam is enough to verify the stabilities of the proton beam.
| CONCLUSION
We proposed periodic QA methods and clarified the stabilities of The system is used for treatment of lung, liver, pancreas, and other tumors with respiratory motion.
